Pancreatic Cancer Research

ResearcherChongqing UniversityActive in the last 2 years

Fuming Xie

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5046978177. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 11

  1. Targeting tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.iliver.2026.100243↗
  2. Tumor microenvironment remodeling in pancreatic cancer liver metastasis. Last author DOI 10.1016/j.iliver.2025.100209↗
  3. A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under… Co-author DOI 10.1186/s12943-025-02500-w↗
  4. Circular RNA in Pancreatic Cancer: Biogenesis, Mechanism, Function and Clinical Application. Co-author DOI 10.7150/ijms.107773↗
  5. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. Co-author DOI 10.1016/j.drup.2023.101027↗
  6. CircPTPRA promotes the progression of pancreatic ductal adenocarcinoma via the miR-140-5p/LMNB1 axis. Co-author DOI 10.1002/cam4.5869↗
  7. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1138238↗
  8. Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1218781↗
  9. Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by act… Co-author DOI 10.1186/s12935-022-02835-0↗
  10. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation. First author DOI 10.1016/j.ygeno.2020.11.010↗
  11. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription. Co-author DOI 10.7150/thno.44278↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaizhi Wang · 9 shared papers, 2020–2025 · strength 1.50
  2. Jingyang Yin · 5 shared papers, 2022–2025 · strength 0.95
  3. Yuxi Long · 3 shared papers, 2025–2026 · strength 0.93
  4. Shixiang Guo · 6 shared papers, 2020–2024 · strength 0.84
  5. Lei Cai · 3 shared papers, 2022–2026 · strength 0.70
  6. Luoyingzi Xie · 2 shared papers, 2025–2026 · strength 0.70
  7. Bojing Chi · 4 shared papers, 2022–2023 · strength 0.62
  8. Wen Fu · 4 shared papers, 2022–2023 · strength 0.62
  9. Hang Chen · 2 shared papers, 2025 · strength 0.50
  10. Jianyou Gu · 3 shared papers, 2020–2023 · strength 0.42
  11. Jianyou Gu · 2 shared papers, 2022–2024 · strength 0.33
  12. Junfeng Zhang · 2 shared papers, 2020–2024 · strength 0.29
  13. Pijiang Sun · 1 shared paper, 2025 · strength 0.27
  14. Songsong Liu · 2 shared papers, 2020 · strength 0.20
  15. Yingfang Fan · 1 shared paper, 2024 · strength 0.19
  16. Qing Chen · 1 shared paper, 2024 · strength 0.19
  17. Jianbo Li · 1 shared paper, 2022 · strength 0.14
  18. Xianxing Wang · 1 shared paper, 2020 · strength 0.10
  19. Yongsheng Ouyang · 1 shared paper, 2020 · strength 0.10
  20. Yunchao Wang · 1 shared paper, 2020 · strength 0.10
  21. Tao Peng · 1 shared paper, 2020 · strength 0.10
  22. Xuejun Xu · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.